Clinical trial
Vaccine Treatment of Kidney Cancer
NCT00089778 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00089778 |
|---|---|
| Title | Vaccine Treatment of Kidney Cancer |
| Official title | Immunization of Patients With Renal Cancer Using HLA-A2 and HLA-A3-Binding Peptides From Fibroblast Growth Factors 5 (FGF-5) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug, Other |
| Interventions | 117-126:Fibroblast growth factor 5 (FGF-5), Fibroblast growth factor 5 (FGF-5):172-176/217-220, IL-2 |
| Enrollment | 11 |
| Start date | Sep 10, 2004 |
| Primary completion | Aug 5, 2008 |
| Completion | Aug 5, 2008 |
| First posted | Aug 13, 2004 |
| Last update posted | Aug 1, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: